These findings are consistent with previous reports on the immune landscape of TP53- and RUNX1-mutated AML (47, 48) and on the inverse correlation between immune infiltration and percentage of blasts, i.e., tumor purity (49). The gene discussed is TP53; the disease is neoplasm.